Merck & Co., Inc. (BVMF:MRCK34)

Market Cap	1.58T +9.2%
Revenue (ttm)	358.08B +1.3%
Net Income	100.54B +6.6%
EPS	40.10 +8.0%
Shares Out	n/a
PE Ratio	15.71
Forward PE	23.64
Dividend	1.53 (1.95%)
Ex-Dividend Date	Dec 12, 2025

Volume	9,346
Average Volume	3,895
Open	78.40
Previous Close	77.01
Day's Range	78.40 - 80.00
52-Week Range	51.60 - 80.20
Beta	0.30
RSI	69.51
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: MRCK34

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD